Wednesday , October 23 2019
Home / BUSINESS / Glenmark’s arm receives USFDA’s final approval for Hydrocortisone Valerate Cream

Glenmark’s arm receives USFDA’s final approval for Hydrocortisone Valerate Cream

Glenmark Pharmaceuticals’ subsidiary — Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Hydrocortisone Valerate Cream USP, 0.2%, a generic version of Westcort Cream, 0.2%, of Sun Pharmaceutical Industries Inc.

According to IQVIA sales data for the 12-month period ending August 2018, the Westcort Cream, 0.2% market achieved annual sales of approximately $17.0 million.

The company’s current portfolio consists of 139 products authorized for distribution in the US marketplace and 60 ANDA’s pending approval with the USFDA. In addition to these internal filings, the compnay continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).